NCT07077369View on ClinicalTrials.gov

WGc-0201 Plus Tislelizumab in HCC With High Risk of Recurrence and Metastasis After Radical Therapy

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

10

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2028

Conditions

Hepatocellular Carcinoma (HCC)

Interventions

BIOLOGICAL

WGc-0201 injection

WGc-0201 injection

DRUG

Tislelizumab

Tislelizumab, 200mg

All Listed Sponsors

lead

West China Hospital

OTHER